Bildkälla: Stockfoto

Medivir Q3 2024: Next Step NDA - Redeye

Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits oncology, and a median time to progression of 10.9 months for fostrox has been established.

Redeye comments on Medivir's Q3 report. We make changes to our base case as IGM Biosciences exits oncology, and a median time to progression of 10.9 months for fostrox has been established.
Börsvärldens nyhetsbrev
ANNONSER